UCANACT secures €800K to advance brain-computer communication technology

Utrecht, September 15, 2026 – UCANACT, a Dutch neurotechnology startup developing brain-computer interface technology for people with motor disabilities, has secured €800,000 in pre-seed funding. The investment round was led by LUMO Labs and Utrecht Holdings Seed Fund.

People living with severe motor disabilities caused by motor neuron disease, stroke, trauma and other conditions can lose the ability to speak independently. UCANACT is developing a brain-computer interface that translates brain signals directly into computer actions and speech that helps people communicate and interact with the world around them.

Built on decades of brain-computer interface research at UMC Utrecht, UCANACT combines advances in brain science, artificial intelligence and neurotechnology. Its technology is designed to enable independent communication at home through automated system training which minimizes the support required from technicians and caregivers.

“We want to transform and integrate advances in brain science, AI and neurotechnology into neural devices for the benefit of people suffering from severe paralysis, enabling them to regain autonomy and participate in society,” said UCANACT.

“UCANACT is applying advanced technology to a deeply human and urgent need,” added Thomas Hannes of LUMO Labs. “They are developing technology that could give people with severe motor disabilities greater independence and a stronger connection to the world around them. Backed by decades of research, proprietary technology and an experienced team, the company has a strong foundation for turning that ambition into a real-world solution.”

“UCANACT represents the kind of science-based innovation that the Utrecht Holdings Seed Fund is designed to support,” said Timo Koopmans, Investment Manager at Utrecht Holdings Seed Fund. “Building on the BCI research at UMC Utrecht, this technology has the potential to improve the quality of life and autonomy for people living with severe motor impairments. We are proud to back the company and team as they bring their solution to the market.”

The investment will be used for technical product development, clinical studies, market-access research and early commercialization activities. UCANACT will also expand its team with key hires to strengthen its technical capabilities and further develop its business strategy.

UCANACT’s work has been partially funded by the ALS Association and supported by the TTT-AI voucher, an MIT Feasibility Grant and NWO Take-off I.